Company ProfilePremium

Kanoria Chemicals & Industries Ltd.

Company Profile Analysis

Ticker: KANORICHEM.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Kanoria Chemicals & Industries Ltd. - Company showcase

Year Founded & Workforce

1960

389 Employees

Kanoria Chemicals & Industries Ltd. logo

Kanoria Chemicals & Industries Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Kanoria Chemicals & Industries Ltd. Overview

Kanoria Chemicals & Industries is a 65-year-old, promoter-controlled Indian manufacturer of formaldehyde-chain "Alco Chemicals": formaldehyde, pentaerythritol (Penta/PE), hexamine, sodium formate, phenolic resins and acetaldehyde. It runs three plants at Ankleshwar (Gujarat), Visakhapatnam and Naidupeta (Andhra Pradesh), with combined formaldehyde capacity of about 1,400 tonnes per day (TPD). The products go mainly into construction, infrastructure, paints and coatings, plywood/laminates, pharmaceuticals and agrochemicals. The company says it leads the Indian market in most of its products, and it is the petitioner behind India's pentaerythritol anti-dumping duties. Through its wholly owned Ethiopian subsidiary, Kanoria Africa Textiles PLC, it also makes integrated denim. In July 2025 it exited a loss-making European automotive-electronics subsidiary (APAG), and it is now repositioning as a focused chemicals company under a "Vision-2030" plan. That plan centres on specialty derivatives (Triacetin, Penta derivatives), resin and formaldehyde capacity, and renewable-energy-led cost reduction. The company is small-cap (about ₹800 Cr market value), BB+-rated, and moderately leveraged.


What the company does

KCIL makes commodity and semi-specialty chemical intermediates on a methanol-to-formaldehyde chain. Methanol (bought in) is oxidised to formaldehyde. Formaldehyde is either sold to resin, plywood/laminate and chemical customers, or used captively to make:

  • Pentaerythritol (PE / "Penta"), a polyol for alkyd resins in paints and coatings, plus inks, lubricants and explosives intermediates. Sodium formate is a co-product of the Penta process.

Hexamine: (hexamethylenetetramine), used in rubber curing, phenolic moulding compounds, pharmaceuticals and fuel tablets. A significant share is exported to Europe and the USA.

  • Phenolic resins, from phenol plus formaldehyde, for foundry, friction, laminates and abrasives.

  • Acetaldehyde, listed in the FY25 MD&A product portfolio.

The FY25 MD&A says Penta, hexamine and phenolic-resin process technologies were developed in-house and refined over time for global cost and quality competitiveness. It also says the formaldehyde plants use modern technology that gives cost and quality advantages.

The second continuing business is Textiles: an integrated denim mill in Ethiopia run through Kanoria Africa Textiles PLC (KAT), a wholly owned subsidiary.

The third, now discontinued, business was Electronics/Automotive. APAG Holding AG (Switzerland) and its subsidiaries in Switzerland, the Czech Republic, Germany (CoSyst Control Systems GmbH) and North America designed and manufactured electronic control units and mechatronic modules for automotive and industrial OEMs. APAG ceased to be a subsidiary with effect from 31 July 2025 and is reported under discontinued operations in FY26.

A fourth small activity, a 5 MW solar power plant at Village Bap, Jodhpur (Rajasthan), was sold on a slump-sale basis in FY25 (approved 3 May 2024; buyer SML Electricals India; consideration about ₹8.2 Cr per Reuters).

Company's own description (paraphrased from the FY25 MD&A)

Management describes the Alco Chemicals Division as serving construction, infrastructure, paints, pharma and agrochemicals. Its portfolio is formaldehyde, pentaerythritol, hexamine, sodium formate, phenolic resins and acetaldehyde, made at Ankleshwar, Vizag and Naidupeta. Management claims market leadership in most of these products and a significant presence in the rest. Screener's business summary, drawn from company documents, describes KCI as a maker of chemical intermediates and specialities focused on infrastructure and construction.

Business and revenue model

DimensionCharacterisation
Revenue modelAlmost entirely product sales (B2B bulk/semi-bulk chemicals; denim fabric). No meaningful service, subscription or licensing revenue disclosed
PricingSpot and contract pricing linked to methanol and phenol costs. Margins are spread-driven (product price minus methanol/phenol cost) and exposed to import parity and anti-dumping protection
Value-chain positionMid-stream. Buys methanol and phenol (largely import-linked, crude/gas-correlated); sells intermediates to downstream formulators
Customer typesPaint and coatings makers (Penta), plywood/laminate and resin makers (formaldehyde), foundry and friction-material makers (phenolic resins), rubber and pharma (hexamine), chemical traders. FY23 BRSR lists paint, plywood, chemicals and foundry customers
End-marketsConstruction and real estate, infrastructure, paints, wood panels/furniture, automotive (friction, rubber), pharma, agrochemicals; garment/denim (Ethiopia)
Capital intensityModerate. Standalone net fixed assets about ₹438 Cr against FY26 revenue of ₹875 Cr
Geographic modelMainly domestic India sales, plus hexamine exports to Europe and the USA (FY26 Directors' Report) and Ethiopian domestic denim sales

Independent characterisation

After the APAG exit, KCIL is a single-chain, India-centric formaldehyde derivatives producer with a small African textile appendage. It is cyclical and spread-based. Earnings swing with three things: (a) methanol and phenol prices against Indian demand, (b) the intensity of Chinese, Middle Eastern and Russian dumping, which management cites repeatedly, and (c) trade-remedy protection (Penta anti-dumping duty imposed May 2024). The economics improved in FY26 for four reasons:

  1. The loss-making APAG was removed. It had an EBITDA loss of ₹6.6 Cr and a net loss of ₹54.6 Cr in FY25.

  2. 345 TPD of new formaldehyde and 18 TPD of new hexamine capacity at Ankleshwar became operational (September 2024).

  3. The Penta anti-dumping duty took effect.

  4. Ethiopia recovered.

Q1FY27 standalone revenue of about ₹430 Cr, roughly half of the whole of FY26 standalone revenue (₹875 Cr), implies a step change. The sources reviewed do not explain it, so the durability of this run-rate is the central analytical question.

Strategy

Stated strategy: "Vision-2030"

The FY25 MD&A describes Vision-2030 as a long-term plan covering new product lines and expansion of the existing portfolio. Its stated aim is substantial growth in revenue and profitability by 2030. The FY26 Directors' Report and the September 2026 AGM presentation restate the themes:

  1. Specialty diversification: Triacetin and Penta derivatives / multi-purpose specialty plant, in advanced construction and "expected to be commissioned shortly".

  2. Core capacity: further formaldehyde and phenolic-resin capacity. Resin expansion is under construction; formaldehyde addition is being "actively pursued".

  3. R&D and new product development (NPD): a dedicated NPD cell, with the R&D team and infrastructure "significantly augmented" in FY26. Focus areas are new applications, waste elimination and "waste-to-wealth".

  4. Cost reduction: renewable power (about 80% of Ankleshwar), energy-efficiency projects (Penta steam optimisation, hydro turbine, IRIS monitoring, 66 kV grid), supply-chain strengthening.

  5. Portfolio focus: exit from non-core and loss-making businesses (solar FY25; APAG FY26); targeted reinvestment in KAT (weaving expansion).

  6. Funding: promoter support via ₹49.5 Cr of 7% NCRPS for capex, working capital and general corporate purposes.

Initiatives in the last 24 months (Oct 2024–Oct 2026)

InitiativeDateStatus / target
345 TPD formaldehyde + 18 TPD hexamine at AnkleshwarCommissioned Sep 2024Operating; formaldehyde 1,400 TPD, hexamine 52 TPD
Triacetin plantConstruction started FY25; advanced FY26Commissioning "shortly" (Sep 2026)
Multi-purpose plant (Penta derivatives, specialties)Construction started FY25Commissioning "shortly"
Phenolic resin capacity additionsOne tranche commissioned FY26; further tranche under constructionCapacity not disclosed
Group-captive hybrid wind-solar power at AnkleshwarAdopted FY26About 80% of unit's power; similar project under discussion at Vizag
Phenol Recovery PlantStabilised at Ankleshwar; under implementation at Vizag—
Ion-exchange treatment of hexamine waste streamCommissioned at Ankleshwar and Vizag—
Carbon footprint assessmentFY26Company claims one of the lowest emission intensities among comparable producers (self-reported)
APAG divestmentApproved 29 Jul 2025; effective 31 Jul 2025Tranche 2 (14.3%) in FY2029-30
KAT weaving expansionUnder board evaluation"Moderate" capex
NCRPS ₹49.5 CrAllotted 18 Apr 2026Funds capex/working capital

Medium-term financial targets / guidance

No quantified revenue, margin or return targets have been published in the sources reviewed. Vision-2030 is qualitative ("substantial revenue and profitability growth by 2030"). No earnings calls or investor days are held or transcribed.

Products & Services

Chemicals segment (continuing)

ProductDescription and applicationsCapacity / plantTarget customersNotes
Formaldehyde (aqueous, typically 37%)C1 building block from methanol oxidation; used for urea-, melamine- and phenol-formaldehyde resins and as captive feed for Penta, hexamine and phenolic resinsAbout 1,400 TPD total across Ankleshwar, Visakhapatnam and Naidupeta, after the 345 TPD Ankleshwar plant (Sep 2024)Plywood/laminate/MDF makers, resin producers, chemical manufacturersFY23 BRSR lists formaldehyde as the largest product at about 51% of turnover. Further formaldehyde capacity is under evaluation (Vision 2030)
Pentaerythritol (Penta / PE)Polyol for alkyd resins (paints/coatings), rosin esters (inks), synthetic lubricants, PETNAnkleshwar (capacity not disclosed in sources reviewed)Paint and coatings majors, ink and resin makersKCIL and Asian Paints are described as India's two major Penta producers. Protected by anti-dumping duty since 16 May 2024. Process developed in-house
Sodium formateCo-product of Penta; used in leather tanning, textile dyeing, de-icing, drilling fluidsAnkleshwarLeather, textile and oilfield chemicals usersManagement flags cheaper imports as a threat
HexamineHexamethylenetetramine; rubber vulcanisation accelerator, phenolic moulding curing agent, pharma (methenamine), fuel tablets52 TPD total after the 18 TPD Ankleshwar addition (Sep 2024); also produced at Vizag (Ion Exchange waste treatment at both)Rubber/tyre, phenolic moulders, pharma, exportersLarge export share to Europe and the USA. FY26 exports hurt by weak European demand and high US tariffs
Phenolic resinsPhenol-formaldehyde resins (novolac/resol) for foundry, friction, abrasives, laminatesVisakhapatnam: originally 3,000 MTPA automated plant. Additional capacity commissioned in FY26 and a further expansion under construction (amounts not disclosed)Foundry, brake-lining/friction, abrasives, laminate makersPhenol Recovery Plant stabilised at Ankleshwar; similar unit being built at Vizag
AcetaldehydeIntermediate for acetic acid, pyridines, PentaPlant location not specified in sourcesChemical/pharma intermediates makersListed in FY25 MD&A portfolio
Triacetin (pipeline)Glycerol triacetate; plasticiser for cigarette filters, food/pharma excipient, foundry sand hardenerNew plant in advanced construction (FY26 Directors' Report); "expected to be commissioned shortly" (AGM, Sep 2026)Tobacco filter, food, pharma, foundry customersVision-2030 diversification product from the NPD cell
Penta derivatives and specialty chemicals (pipeline)Multi-purpose plant for Pentaerythritol derivatives (e.g., Penta esters; specific products not disclosed) and other specialtiesMulti-purpose plant in advanced constructionLubricants, coatings, specialty polymer customersVision-2030

Pricing model: no list prices are disclosed. Pricing is market/contract based and tracks methanol and phenol costs, so margins are spread-driven.

Textiles segment (continuing)

OfferingDescriptionCapacity dataCustomers
Denim fabric (integrated spinning–weaving–processing)Integrated denim manufacturing in Ethiopia via KATCapacity utilisation 66% FY26 (56% FY25). Board evaluating extra weaving capacity at moderate capex, given surplus capacity in other departmentsEthiopian garment makers/domestic market; exports viable after devaluation (management view)

Discontinued portfolios (for reference)

Former offeringDescriptionExit
APAG/CoSyst electronic control units, mechatronic modules, automotive and industrial electronics; ECU R&D and engineering servicesContract design and manufacture for Western automotive and industrial OEMs (ICE and EV platforms)Deconsolidated 31 Jul 2025; about 14.3% residual stake
Solar power (5 MW PV, Jodhpur, REC scheme)Merchant/REC-linked power generation since 2012Sold FY25 (about ₹8.2 Cr)
Chloro chemicals (caustic soda, chlorine, chlorinated paraffin, poly aluminium chloride, water-treatment chemicals, lindane, aluminium chloride) and captive coal power (2 × 25 MW) at RenukootFormer integrated chlor-alkali complexSold to Aditya Birla Chemicals, 2011
Industrial alcohol (15 million litres p.a., 1994)Alcohol-based intermediates—

Financial Narrative

Basis:

  • Consolidated figures for FY22–FY25 include APAG.

  • FY26 is continuing operations only; APAG sits in discontinued operations, and FY25 is restated to ₹754.3 Cr in the FY26 report.

  • Primary series: Screener.in consolidated and standalone (from audited annual reports), cross-checked against Anand Rathi, the FY25 MD&A and the FY26 Directors' Report.

  • All figures in INR crore unless stated.

Consolidated income statement

Notes:

Owners' profit: It is derived as EPS × about 4.37 crore shares. FY25 owners' loss of ₹83.6 Cr matches the Fyers/Simply Wall St EPS of -19.13 to -19.34 (Simply Wall St reports net loss of ₹84.5 Cr and EPS of -19.34, a small discrepancy). FY26 owners' profit of ₹120.8 Cr matches MarketsMojo and Fyers. The total profit of ₹113.2 Cr includes the non-controlling interest's share of APAG's pre-disposal losses.

FY26 other income: of ₹103 Cr includes the ₹97.65 Cr gain on loss of control of APAG (discontinued operations). The FY25 figure is negative because of the ₹29.4 Cr goodwill impairment and other exceptional items.

FY26 tax: includes a ₹21.43 Cr deferred-tax remeasurement credit from adopting the new tax regime (Section 200, Income Tax Act 2025).

Gross profit: is not disclosed in sources reviewed. Aggregator gross-margin series (e.g., TipRanks) are internally inconsistent and are not used.

Revenue CAGR:

  • Consolidated FY22–FY25 (like-for-like, including APAG): about 3.9%.

  • Consolidated FY22–FY26 as reported: about -8% (distorted by the APAG deconsolidation).

  • Standalone FY21–FY26: about 17.7% (Screener: 18% 5-year).

  • Standalone FY22–FY26: about 7.8%.

Standalone income statement (the continuing chemicals business)

Notes:

  • FY24–FY26 EBITDA, pre-exceptional profit and exceptional items are from the FY25 MD&A and FY26 Directors' Report (₹ million converted).

  • FY22–FY23 EBITDA is Screener operating profit plus other income, so it is only approximately comparable.

  • FY26 exceptional item: ₹10.64 Cr impairment of the APAG investment.

  • FY25 exceptional items: ₹44.99 Cr impairment of foreign subsidiaries.

  • FY26 standalone tax was a credit of ₹5.74 Cr.

Balance sheet

Not disclosed in sources reviewed:

Cash and short/long-term debt split: Cash appears small: TipRanks gives a consolidated cash ratio of about 0.02. Net debt is therefore approximated as gross borrowings.

Working capital: Screener working-capital days are 17, 8, 9, -4 and -14 (FY22–FY26, consolidated); a negative figure implies payables and other current liabilities exceed receivables plus inventory.

Current ratio: (standalone, MD&A): 1.14 (FY24), 0.93 (FY25). FY26 not disclosed.

Contingent liabilities: about ₹178 Cr (Screener, latest).

Post-balance-sheet: ₹49.5 Cr of 7% NCRPS was issued in April 2026. Under Ind AS this is likely classified as a financial liability; Q1FY27 standalone other income included a ₹6.30 Cr fair-valuation gain on the NCRPS (aggregators state ₹63.0 crore, a lakh/crore error).

Cash flow

Notes:

  • The FY23 "dividends paid" figure is the derived cash outflow for the FY22 dividend of about ₹1 per share × 4.37 crore shares (timing assumed).

  • No buybacks have been authorised or executed in the period.

Ratios

Notes:

  • Ratios are computed from the tables above.

  • ROIC is not separately disclosed; ROCE is used as a proxy.

  • FY26 ROE and ROA are inflated by the ₹97.65 Cr one-off gain. Excluding it and the ₹21.4 Cr deferred-tax credit, FY26 adjusted owners' profit is roughly ₹1–2 Cr on a continuing basis. That is consistent with the Anand Rathi continuing PAT of ₹32.4 Cr less the deferred-tax credit and exceptional reversal; derived, approximate.

  • The standalone MD&A interest-coverage ratio is 2.92x (FY24) and 3.65x (FY25).

Commentary on trends, inflections and drivers

FY22 (peak of the pre-crisis cycle). Standalone operating margin hit 9% on post-COVID restocking and strong formaldehyde/Penta spreads. Standalone profit was ₹25 Cr and a dividend was paid. On a consolidated basis, APAG's thin margins (consolidated operating margin about 5%) and Ethiopia's foreign-currency shortages limited group profit to ₹2.2 Cr.

FY23–FY24 (spread compression). Standalone operating margin collapsed to 3% and then 1%. Management attributes this to a global surplus of basic chemicals, Chinese/Middle-Eastern/Russian dumping and weak demand in the second half of the year. Consolidated losses widened as APAG (FY24 net loss ₹37.5 Cr) and KAT (₹16.6 Cr) bled. Debt stayed at about ₹510 Cr, and interest coverage fell below 2x.

FY25 (operational recovery in India, structural crisis abroad). Standalone revenue rose 18% and EBITDA 69% to ₹53.6 Cr, helped by:

  • the Penta anti-dumping duty (May 2024);

  • the new Ankleshwar capacity (September 2024), despite the roughly three-week GPCB closure (20 September–10 October 2024).

However, ₹45 Cr of standalone impairments and a ₹29.4 Cr consolidated goodwill write-off on APAG, plus APAG's EBITDA turning negative (customers insourcing programmes, OEM price-downs, ECU R&D under-utilisation) and KAT's Birr-devaluation loss, produced a consolidated net loss of ₹108 Cr. Consolidated debt to EBITDA exceeded 14x; this is the trough of balance-sheet stress.

FY26 (portfolio surgery and turnaround).

  • APAG was deconsolidated. The ₹97.65 Cr gain on loss of control dominates reported profit; no cash consideration was received in tranche 1.

  • Consolidated borrowings halved from ₹595 Cr to ₹291 Cr, mainly because APAG's debt left the balance sheet.

  • Standalone revenue grew 29% to ₹875 Cr and EBITDA 52% to ₹81.6 Cr, a 9.3% margin. Management credits cost optimisation, R&D-driven process and product innovation, and supply-chain strengthening. It names headwinds: dumping, raw-material volatility, and weaker hexamine exports to Europe (demand) and the USA (tariffs).

  • KAT's turnaround (EBITDA ₹19.25 Cr) added a second profit stream.

Q1FY27 (inflection, partly unexplained).

  • Consolidated revenue ₹460.4 Cr, up 129% YoY and 51% QoQ.

  • EBITDA ₹51.8 Cr (+177% YoY), net profit ₹26.4 Cr.

  • Standalone revenue ₹430.0 Cr (+130% YoY), standalone net profit ₹26.4 Cr. This includes the ₹6.3 Cr NCRPS fair-value gain within ₹9.0 Cr of other income.

  • The consolidated quarterly revenue path is ₹201 Cr (Q1FY26), ₹210 Cr (Q2), ₹266 Cr (Q3), ₹304 Cr (Q4), ₹460 Cr (Q1FY27).

The filings and summaries reviewed do not explain the scale of the jump. A doubling of revenue on a broadly unchanged capacity base (1,400 TPD formaldehyde; new specialty plants not yet commissioned per the AGM) points to a large realisation or price effect, plausibly methanol-linked pass-through, together with volume gains. Margin (EBITDA margin 11.2% consolidated; chemicals segment result margin 9.3%) improved only modestly, which is consistent with a price-led rather than spread-led expansion.

Data conflict on Q1FY26 standalone loss: one summary gives ₹7.67 Cr (ScanX, August 2025) and another ₹4.67 Cr (Q1FY27 comparative per Multibagg/ScanX). The latter is probably the restated comparative.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryRelationshipActivityStatus

Kanoria Chemicals & Industries Ltd

India

Parent

Alco Chemicals (3 plants)

Active

Kanoria Africa Textiles PLC (KAT)

Ethiopia

100% subsidiary (per FY26 Directors' Report)

Integrated denim

Active. A January 2025 board approval to dispose of 8,684,325 shares (13.79%) was disclosed; the FY26 report still calls KAT wholly owned, so completion is not confirmed

APAG Holding AG

Switzerland

Former subsidiary (55% before dilution); about 14.3% residual stake after first tranche

Automotive/industrial electronics holding

Deconsolidated w.e.f. 31 Jul 2025

APAG Elektronik AG; APAG Elektronik s.r.o.; CoSyst Control Systems GmbH; APAG Elektronik LLC; APAG Elektronik Corp.; Adapt Control Systems GmbH; Adapt Control Systems Inc.

Switzerland, Czech Republic, Germany, North America, Canada

Former step-down subsidiaries

ECU/mechatronics design and manufacture

Deconsolidated with APAG

Segment / entity revenue (INR Cr)

Segment / entity revenue (INR Cr)FY2024FY2025FY2026

Chemicals (standalone revenue from operations)

576.9678.3875.3

Textiles (KAT revenue from operations)

108.176.0106.1

Electronics/Automotive (APAG revenue from operations)

790.1782.40

Consolidated revenue as reported

1,4751,537981

Segment EBITDA (INR Cr)

Segment EBITDA (INR Cr)FY2024FY2025FY2026

Chemicals (standalone EBITDA incl. other income, before exceptional items)

31.753.681.6

Electronics/Automotive (APAG EBITDA)

27.7-6.60

Segment net profit (INR Cr)

Segment net profit (INR Cr)FY2024FY2025FY2026

APAG net loss

-37.5-54.60

KAT net loss

-16.6-31.20

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

1,3691,5781,4751,537981

Operating profit before other income (INR Cr)

6872523171

Other income (INR Cr)

291016-19103

EBITDA as reported by Anand Rathi (INR Cr)

97.082.772.040.693.8

Finance costs (INR Cr)

2736434632

Depreciation (INR Cr)

5759596335

Profit before tax incl. discontinued gain (INR Cr)

13-12-34-96107

Profit before tax, continuing ops, Anand Rathi (INR Cr)

13.1-12.2-36.0-97.326.6

Net profit, total (INR Cr)

2.2-12.9-55.3-108.2113.2

Net profit attributable to owners (INR Cr)

6.8-8.8-38.4-83.6120.8

EPS basic, owners (INR)

1.56-2.01-8.79-19.1327.64

EPS diluted (INR)

1.56-2.01-8.79-19.1327.64

Dividend per share (INR)

1.00000

Margin metric (%)

Margin metric (%)FY2022FY2023FY2024FY2025FY2026

Operating margin before other income (%)

5.04.63.52.07.2

EBITDA margin, Anand Rathi basis (%)

7.15.24.92.69.6

Net margin, total profit (%)

0.2-0.8-3.7-7.011.5

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

649675577678875

Operating profit before other income (INR Cr)

591963955

Operating margin (%)

93166

EBITDA incl. other income, before exceptional items (INR Cr)

704031.753.681.6

Finance costs (INR Cr)

910121619

Depreciation (INR Cr)

2121182023

Profit before exceptional items and tax (INR Cr)

409217.539.3

Exceptional items (INR Cr)

000-45.0-10.6

Net profit (INR Cr)

256-1-3834.4

EPS basic (INR)

5.721.36-0.25-8.697.88

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Financial Ratios (x)

Consolidated balance sheet (INR Cr)FY2022FY2023FY2024FY2025FY2026

Equity share capital

2222222222

Reserves

577584579499551

Total equity (excl. NCI where shown)

599606601521573

Borrowings (total debt)

475510509595291

Other liabilities

329366380382253

Total liabilities and equity

1,4031,4811,4901,4981,117

Net fixed assets

863882850865727

Capital work in progress

1010474632

Investments

2217161459

Other assets (incl. working capital, cash)

507573578574299

Debt to equity (x)

0.790.840.851.140.51

Balance Sheet and Financial Ratios (x) by Standalone Balance Sheet

Standalone balance sheet (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total equity

639641639601638

Borrowings

97124143197183

Net fixed assets

400405380423438

Capital work in progress

50321426

Investments

209218210163183

Total assets

9019079449861,051

Debt to equity (x)

0.150.190.220.330.29

Consolidated cash flow (INR Cr)

Consolidated cash flow (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

8326381571

Investing cash flow

-43-29-50-59-8

Financing cash flow

-533541-58

Capital expenditure (derived CFO minus FCF)

4238757951

Free cash flow

41-12-37-6420

Dividends paid (derived)

04.4000

Share buybacks

00000

Standalone cash flow (INR Cr)

Standalone cash flow (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

4925261174

Capital expenditure (derived)

1212323344

Free cash flow

3713-6-2230

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE consolidated, owners' profit ÷ closing equity (%)

1.1-1.5-6.4-16.021.1

ROA consolidated, total profit ÷ total assets (%)

0.2-0.9-3.7-7.210.1

ROCE consolidated, Screener (%)

411-26

ROCE standalone, Screener (%)

71147

Debt to equity consolidated (x)

0.790.840.851.140.51

Gross debt to EBITDA consolidated (x)

4.96.27.114.73.1

Interest coverage, EBITDA ÷ finance cost (x)

3.62.31.70.92.9

Asset turnover consolidated (x)

0.981.070.991.030.88

Cash conversion cycle consolidated (days)

6361686334

Cash conversion cycle standalone (days)

3840294228

Debtor days consolidated

4645465650

Inventory days consolidated

97911048455

Payable days consolidated

8075827870

Region (operating-entity proxy) revenue (INR Cr)

Region (operating-entity proxy) revenue (INR Cr)FY2024FY2025FY2026

India (standalone chemicals)

576.9678.3875.3

Africa (Ethiopia, KAT)

108.176.0106.1

Europe and North America (APAG)

790.1782.40

Region growth YoY (%)

Region growth YoY (%)FY2025FY2026

India (standalone chemicals)

17.629.0

Africa (Ethiopia, KAT)

-29.739.6

Europe and North America (APAG)

-1.0-100

Capital Markets

ItemValueSource / date

Last price

₹182.10

ScanX / IIFL, 6 Oct 2026 close

Market capitalisation

₹795.66 Cr

ScanX

Recent prices

₹199.62 (29 Sep 2026); ₹198.77 (30 Sep 2026); ₹149.69 (7 Aug 2026); ₹121 (late May 2026)

IIFL; Screener

52-week low

about ₹55.7 (Screener range; date within the last 12 months, not exact)

Screener

1-year return

+127.7%

ScanX

6-month return

+183.3%

ScanX

5-year return

-14.6%

ScanX

Share price performance (%)

1Y

5Y

KANORICHEM total price return (%)

127.7-14.6

Valuation Snapshot

MultipleValueBasis

P/E (TTM, reported)

about 5.0x (ScanX: 5.21x)

TTM owners' profit about ₹160 Cr including APAG gain and deferred-tax credit

P/E (TTM, ex one-offs, rough)

about 20–25x

Excludes ₹97.65 Cr gain, ₹21.4 Cr deferred-tax credit, ₹6.3 Cr NCRPS gain; derived

P/B

about 1.4x

Consolidated book value about ₹131/share (Mar 2026)

EV

about ₹1,136 Cr

Market cap ₹796 Cr + borrowings ₹291 Cr (Mar 2026) + NCRPS ₹49.5 Cr; cash assumed negligible

EV/EBITDA (FY26)

about 12.1x

EBITDA ₹93.8 Cr

EV/EBITDA (TTM to Q1FY27)

about 9.0x

TTM EBITDA about ₹126.9 Cr (FY26 − Q1FY26 ₹18.7 Cr + Q1FY27 ₹51.8 Cr)

EV/Sales (TTM)

about 0.92x

TTM revenue about ₹1,240 Cr

Dividend per share (INR)

Dividend per share (INR)FY2021FY2022FY2023FY2024FY2025FY2026

DPS (INR)

01.00000

Credit Ratings

AgencyRatingOutlook

CARE Ratings: long-term bank facilities

CARE BB+

Stable

CARE Ratings: short-term bank facilities

CARE A4+

—

Moody's / S&P / Fitch

Not rated

—

Analyst Conclusions

Management guidance

Quantitative guidance: none.

Qualitative (AGM, September 2026; FY26 Directors' Report): - Triacetin and Penta-derivative plants to be commissioned "shortly".

  • Formaldehyde and resin capacity additions being pursued.

  • Cost-reduction programmes continuing.

  • KAT sales momentum expected to sustain, with weaving expansion under evaluation.

  • Geopolitics and high tariffs flagged as headwinds.

  • Demand outlook tied to Indian GDP growth.

Consensus

No consensus estimates exist (no sell-side coverage).

Bull case

  1. Run-rate re-basing. Q1FY27 consolidated revenue of ₹460 Cr and EBITDA of ₹51.8 Cr annualise to about ₹1,800 Cr and about ₹200 Cr, against an EV of about ₹1,136 Cr. Even a partial hold would put the stock on about 6x forward EV/EBITDA.

  2. Mix upgrade. Triacetin and Penta derivatives add higher-margin specialty revenue on top of a captive formaldehyde base, with anti-dumping protection on Penta until about 2029.

  3. Balance-sheet and governance clean-up. Exiting APAG halved debt (₹595 Cr to ₹291 Cr), removed a business losing about ₹55 Cr a year, and the promoter injected ₹49.5 Cr. A CARE upgrade from BB+ could follow sustained profitability.

Bear case

  1. Earnings quality. FY26 profit is about 85% one-off (APAG gain plus deferred-tax credit), and Q1FY27 includes a ₹6.3 Cr NCRPS gain. Continuing-operations profit before the gain was modest, and the Q1FY27 revenue surge is unexplained in disclosures. It may reflect transient price pass-through rather than structural gains (margin expanded only from 9.0% to about 11%).

  2. Cyclicality and dumping. Standalone operating margin fell from 9% (FY22) to 1% (FY24) within two years. Management itself flags Chinese, Gulf and Russian dumping, US tariffs on hexamine and raw-material volatility.

  3. Governance and disclosure discount. CMD duality, 29.6% promoter pledge, related-party APAG co-shareholder, FY26 filing-delay observations, about ₹178 Cr contingent liabilities, negligible institutional ownership, no earnings calls and no R&D or capacity disclosure.

Key catalysts and monitorables (next 12 months)

  • Q2FY27 results (due around November 2026): does revenue stay above ₹400 Cr a quarter, and does EBITDA margin hold above 9.5%?

  • Commissioning dates and early utilisation of the Triacetin and multi-purpose Penta-derivative plants.

  • Methanol and phenol price trajectory, and any reversal of Q1FY27 realisations.

  • Penta import volumes and any DGTR action on hexamine or sodium formate.

  • US tariff developments affecting hexamine exports.

  • KAT weaving-expansion decision and Birr stability.

  • CARE rating action.

  • Changes in promoter pledge.

  • NCRPS accounting (fair-value movements through P&L).

  • Status of the KAT 13.79% stake sale.

  • Gujarat environmental compliance at Ankleshwar.

Analyst verdict

Kanoria Chemicals & Industries is at a genuine inflection point, but the reported numbers overstate the change. Strip away the ₹97.65 Cr non-cash gain on APAG and the ₹21.4 Cr deferred-tax credit, and FY26 was a recovery year rather than a breakout. The core chemicals franchise raised EBITDA to ₹81.6 Cr at a 9.3% margin, and the Ethiopian denim unit returned to positive EBITDA. Exiting APAG was strategically correct: it removed a structurally challenged, sub-scale European automotive-electronics business that was absorbing capital and management attention. It also halved consolidated debt and leaves a small residual option (14.3%, to be sold in FY2029-30).

What makes the equity story newly interesting is Q1FY27. Standalone revenue of ₹430 Cr in a single quarter is almost half of FY26's total, and the market has reacted (+128% over one year). The company has not explained the scale of this jump. With capacity broadly unchanged and margins up only modestly, investors should assume a meaningful price or pass-through component until proven otherwise. If even two-thirds of the Q1 run-rate persists and the Triacetin and Penta-derivative plants start on schedule, the stock at about 9x trailing EV/EBITDA would still look undemanding for an integrated formaldehyde-chain leader with trade protection on its flagship Penta.

The discount has identifiable causes: commodity cyclicality, dumping exposure, a BB+ balance sheet, promoter-dominated governance with a 29.6% pledge, and thin disclosure (no guidance, no calls, no R&D or capacity-by-product data). Our stance is constructive but evidence-contingent. Q2 and Q3 FY27 prints showing sustained revenue above ₹400 Cr a quarter at double-digit EBITDA margins, specialty-plant commissioning, and a reduced pledge would together justify a re-rating. Any reversion toward the FY26 quarterly run-rate (₹250–300 Cr) would expose the current price as anticipating more than the business has yet proven.


APPENDIX: SOURCES

  1. Kanoria Chemicals & Industries, FY2025-26 (66th) Annual Report, Directors' Report (via IndiaInfoline): https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/reports/directors-report

  2. Kanoria Chemicals & Industries, FY2024-25 Management Discussion & Analysis (via IndiaInfoline): https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/management-discussions/743

  3. NSE filing: APAG dilution/divestment outcome, 29 Jul 2025: https://a.storyblok.com/f/209886/x/1ae52b60d4/outcome_-dilution-and-divestment-of-equity-stake-in-apag-holding-ag-switzerland-a-meterial-subsidiary-company.pdf

  4. NSE filing: APAG shareholders' agreement, 16 Sep 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_16092025182440_Letter.pdf

  5. NSE filing: GPCB closure order, 21 Sep 2024: https://nsearchives.nseindia.com/corporate/KANORICHEM_21092024175803_Pollution_control_board_complaint.pdf

  6. NSE filing: GPCB order revoked, 9 Oct 2024: https://nsearchives.nseindia.com/corporate/KANORICHEM_09102024165419_Letter.pdf

  7. NSE filing: KAT share disposal, 28 Jan 2025: https://nsearchives.nseindia.com/corporate/KCIL2024_28012025123319_Intimation2801.pdf

  8. NSE filing: Q3FY25 results, 13 Feb 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_13022025161945_Result.pdf

  9. NSE filing: Q2FY26 results, 10 Nov 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_10112025194519_Results.pdf

  10. NSE filing: FY26 results newspaper publication, 26 May 2026: https://nsearchives.nseindia.com/corporate/KANORICHEM_26052026160322_Letter.pdf

  11. BSE filing: Supreme Court order disclosure, 30 Jan 2026: https://bsmedia.business-standard.com/_media/bs/data/announcements/bse/30012026/9be2120e-febe-48a1-b5b9-f8ae3eb876e7.pdf

  12. BSE filing: Supreme Court clarification, 2 Feb 2026: https://bsmedia.business-standard.com/_media/bs/data/announcements/bse/02022026/73e8fd03-a5a7-4b7a-ba6f-f5473fc254ca.pdf

  13. BSE filing: COVID-19 suspension, 25 Mar 2020: https://bseindia.com/xml-data/corpfiling/AttachHis/0116cea5-732c-42b8-9312-b995ce204de4.pdf

  14. BSE filing: BRSR FY2022-23: https://bseindia.com/xml-data/corpfiling/AttachHis/68c7e9a3-bdcb-4f8a-ab6d-01b3e9b8cd5a.pdf

  15. Screener.in, standalone: https://www.screener.in/company/506525/

  16. Screener.in, consolidated: https://www.screener.in/company/KANORICHEM/consolidated/

  17. Anand Rathi, financial results: https://anandrathi.com/stocks/kanoria-chem-inds/financial-results/106525

  18. Fyers, P&L: https://fyers.in/stocks/kanoria-chemicals-industries-ltd/profit-loss

  19. MarketsMojo, annual results: https://marketsmojo.motilaloswal.com/stocks-analysis/financial-annual/kanoria-chem-611963-0

  20. Tickertape: https://www.tickertape.in/stocks/kanoria-chemicals-and-industries-KNRC

  21. Kotak Securities / Kotak Neo, Q1FY26 results: https://www.kotakneo.com/financial-results/kanoria-chemicals-industries-ltd-q1fy2025-26-results

  22. Simply Wall St, FY2025 earnings: https://simplywall.st/stocks/in/materials/nse-kanorichem/kanoria-chemicals-industries-shares/news/kanoria-chemicals-industries-full-year-2025-earnings-1934-lo/amp

  23. ScanX, news hub: https://scanx.trade/stock-news/kanoria-chemicals-industries-ltd

  24. ScanX, Q1FY27 results: https://scanx.trade/stock-market-news/companies/kanoria-chemicals-q1-results-net-profit-surges-673-yoy-to-264-crore/47987120

  25. ScanX, 66th AGM / FY26: https://scanx.trade/stock-market-news/companies/kanoria-chemicals-industries-concludes-66th-agm-shareholder-approval/49896550

  26. Multibagg, Q1FY27: https://www.multibagg.ai/market-pulse/articles/kanoria-chemicals-q1fy27-results-profit-cmspzww2h0v010znx92zvm986

  27. IndiaInfoline, shareholding: https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/share-holding

  28. IndiaInfoline, company summary / history: https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd-share-price-management/summary/743

  29. EnrichMoney, company milestones: https://enrichmoney.in/orca/stock-analysis/kanoria-chem-inds-company-details

  30. InvestYadnya, company profile: https://investyadnya.in/stock-o-meter/kanoria-chemicals-&-industries

  31. Goodreturns, company history: https://www.goodreturns.in/company/kanoria-chemicals-industries/history.html

  32. Walder Wyss, APAG acquisition (2012): https://walderwyss.com/de/news/2012-05-08_kanoria-chemicals-industries-ltd-acquires-apag-holding-ag

  33. Machinist, APAG transaction: https://machinist.in/2025/07/anevolve-asia-investments-uk-to-acquire-majority-stake-in-apag-from-kanoria-chemicals/

  34. Maritime Gateway / Business Line, Penta anti-dumping duty: https://www.maritimegateway.com/india-imposes-anti-dumping-duty-on-pentaerythritol-imports-from-china-saudi-arabia-and-taiwan

  35. Polymers Paint Colour Journal, Penta investigation: https://www.polymerspaintcolourjournal.com/?p=15289

  36. Global Trade Alert, Penta anti-dumping duty: https://globaltradealert.org/state-act/75478-india-definitive-antidumping-duty-on-imports-of-pentaerythritol-from-china-saudi-arabia-and-chinese-taipei

  37. Zerodha / Reuters briefs (solar sale; Penta leadership): https://zerodha.com/markets/stocks/NSE/KANORICHEM/

  38. TipRanks, ratios (used only for cash-ratio indication): https://www.tipranks.com/stocks/in:kanorichem/financials/ratios

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryCommitteesTenure / notes

Rajya Vardhan (R.V.) Kanoria

Chairman & Managing Director

Executive, Promoter

Audit (member), NRC (member), CSR (member), Risk Management (Chairman), Committee of Directors (Chairman)

—

Saumya Vardhan (S.V.) Kanoria (DIN 02097441)

Whole-Time Director

Executive, Promoter

Stakeholders' Relationship, Risk Management, Committee of Directors

Re-appointed for 3 years from 1 Apr 2025; aged about 42 (Feb 2025 disclosure); son of R.V. Kanoria

Madhuvanti Kanoria

Director

Non-Executive, Non-Independent (Promoter)

CSR (Chairperson)

Related to R.V. and S.V. Kanoria per Feb 2025 relationship disclosure

Hemant Kumar Khaitan (DIN 00220049)

Director

Non-Executive, Non-Independent

Stakeholders' Relationship, Committee of Directors

Appointed 4 Sep 2024; re-appointed on rotation at 66th AGM

Meeta Makhan

Director

Independent

Audit (Chairperson), NRC, CSR, Committee of Directors

—

Sidharth Kumar Birla

Director

Independent

NRC (Chairman), Audit, Risk Management

—

Suhana Murshed (DIN 08572394)

Director

Independent

Stakeholders' Relationship (Chairperson), Audit, Committee of Directors

First term 29 Jun 2021–28 Jun 2026; re-appointed for 5 years from 29 Jun 2026 (special resolution, 66th AGM)

Sumanta Chaudhuri

Director

Independent

Audit (from 10 Nov 2025), NRC

—

Executive Leadership Team

NameTitleNotes

R.V. Kanoria

CMD

—

S.V. Kanoria

Whole-Time Director

—

Nirmal Kumar (N.K.) Nolkha

Group Chief Financial Officer

Member, Risk Management Committee

Pratibha Jaiswal

Company Secretary & Compliance Officer

Succeeded Neha Saraf (CS as of Oct 2024); no KMP change in FY26

Governance Overview

MetricValue

Board size

8

Independent directors

4 (50%), meeting the SEBI LODR requirement for an executive-promoter chair

Women directors

3 (37.5%)

Chair/CEO separation

No. The Chairman is also Managing Director and promoter

Board meetings FY26

5

Audit Committee meetings FY26

4

Auditor opinion FY26

Unqualified (statutory and secretarial)

Annual Secretarial Compliance Report FY26

Notes filing delays and minor compliance observations (filed 29 May 2026)

Shareholding Trend

Holder category (%)Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Promoters, Indian

73.4073.4073.4073.4073.40

Promoters, Foreign

0.990.990.990.990.99

Institutions

0.120.110.070.110.12

Non-institutions (retail, corporates, others)

25.4725.4825.5225.4825.48

Competitive Landscape

Competitors by Segment

Product lineNamed competitorsPositioning vs KCIL

Pentaerythritol (India)

Asian Paints (captive/merchant Penta producer; DGTR names KCIL and Asian Paints as the two major domestic producers); importers of Chinese, Saudi and Taiwanese Penta (subject to anti-dumping duty from May 2024)

KCIL described by Reuters as India's top Penta producer; protected by anti-dumping duty

Pentaerythritol (global)

Perstorp (Sweden), Ercros (Spain), Hubei Yihua and other Chinese producers, Chang Chun Group (Taiwan)

Global scale players; KCIL is sub-scale globally

Formaldehyde

Regional Indian producers and captive producers at resin, plywood and laminate makers (e.g., Hexion/Bakelite Synthetics lineage in resins)

KCIL at about 1,400 TPD across three sites claims scale and technology cost advantage; formaldehyde is non-tradable over long distances, favouring a multi-site footprint

Hexamine

Chinese exporters; Indian producers

KCIL exports a significant share; threatened by cheaper imports and US tariffs

Sodium formate

Chinese/imported product

Management cites cheaper imports as a threat

Phenolic resins

Hexion/Bakelite Synthetics, SI Group, Sumitomo Bakelite, Prefere Resins, domestic resin makers

KCIL is a smaller, integrated (captive formaldehyde) player

Denim (Ethiopia)

Other Ethiopian/East African textile mills and Asian imports

KAT cites "intensifying competition in the local market"

Competitor Detail

MetricKCIL (FY26)

Revenue

₹981 Cr consolidated / ₹875 Cr standalone

Revenue growth

+30% (continuing basis)

EBITDA margin

9.6% consolidated / 9.3% standalone

Recent Developments

20 Sep 2024: GPCB closure order on Ankleshwar.

9–10 Oct 2024: order revoked and operations resumed.

13 Feb 2025: Q3FY25 results, with an exceptional impairment based on external valuation.

Company Snapshot

$113.3M

Revenue

389

Employees

1960

Founded

West Bengal, India

Headquarters

SWOT Analysis

Strengths

  • Scale in formaldehyde: about 1,400 TPD across three plants after the 345 TPD Ankleshwar addition (September 2024; FY25 Directors' Report).
  • Market position in Penta: India's top producer (Reuters), with anti-dumping protection of USD 300–499/t on China, Saudi Arabia and Taiwan from 16 May 2024.
  • Improving core profitability: standalone EBITDA rose from ₹31.7 Cr (FY24) to ₹53.6 Cr (FY25) to ₹81.6 Cr (FY26); margin 9.3% in FY26 (FY26 Directors' Report).
  • Delevered balance sheet: consolidated borrowings fell from ₹595 Cr (FY25) to ₹291 Cr (FY26); debt to equity from 1.14x to 0.51x (Screener).
  • Low-cost, low-carbon energy: about 80% of Ankleshwar power from wind-solar hybrid (FY26 Directors' Report).
  • Promoter commitment: ₹49.5 Cr NCRPS infusion in April 2026 and 74.4% promoter holding.
  • Operational safety: zero incidents and zero lost-time injuries at all three units for several consecutive years; Responsible Care Logo at two sites.

Weaknesses

  • Thin, volatile margins: standalone operating margin of 9%, 3%, 1%, 6%, 6% (FY22–FY26, Screener).
  • Weak returns history: consolidated ROE about -3% over 5 years and -4% over 3 years (Screener); losses in FY23–FY25.
  • Low credit rating: CARE BB+ (Stable) / A4+ constrains cost of capital.
  • Governance optics: 29.6% promoter pledge; combined CMD role; FY26 secretarial compliance report notes filing delays.
  • Limited disclosure: no R&D spend, capacity-by-product, customer concentration, geographic split, investor calls or guidance in sources reviewed.
  • Earnings quality: FY26 reported profit is dominated by the ₹97.65 Cr non-cash APAG gain and a ₹21.43 Cr deferred-tax credit; Q1FY27 includes a ₹6.3 Cr NCRPS fair-value gain.
  • Negligible institutional ownership (about 0.1%) and low liquidity.

Opportunities

  • Specialty pipeline: Triacetin and Penta-derivative plants nearing commissioning (AGM, September 2026).
  • Resin capacity: an additional tranche is under construction after the FY26 commissioning.
  • Ethiopia recovery: KAT utilisation rose from 56% to 66% with EBITDA of ₹19.25 Cr; weaving expansion needs only moderate capex.
  • Import substitution and trade defence: history of successful anti-dumping petitions (2012, 2017–2018, 2024) gives a policy tailwind.
  • Revenue momentum: Q1FY27 consolidated revenue of ₹460 Cr annualises well above FY26's ₹981 Cr, if sustained.
  • APAG residual value: the 14.3% stake is to be sold in FY2029-30 under the SHA valuation method, an option on recovery in a recapitalised APAG.

Threats

  • Dumping: management repeatedly cites dumping of products from sanctioned and surplus regions (FY25 MD&A; FY26 Directors' Report).
  • Feedstock volatility: "inordinate fluctuations" in methanol and phenol prices, plus rupee depreciation (FY25 MD&A).
  • Trade barriers: high US tariffs and weak European demand on hexamine exports (FY26 Directors' Report).
  • Environmental regulation: the GPCB ordered Ankleshwar closed within 48 hours in September 2024 (revoked 9 October 2024).
  • Ethiopian macro risk: Birr devaluation of over 130% in FY25, FX shortages and policy change.
  • Anti-dumping sunset: Penta duty expires about May 2029 unless extended.
  • Contingent liabilities: about ₹178 Cr (Screener), about 31% of FY26 consolidated equity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Step-down subsidiaries Adapt Control Systems GmbH (Germany, EUR 25k) and Adapt Control Systems Inc. (Canada, CAD 10k) formed via CoSystLast APAG expansion move before exit
10 May 2025Postal ballot approved S.V. Kanoria's re-appointment as WTD (3 years from 1 Apr 2025) and related-party transactionsGovernance continuity
21 May 2025Q4FY25 results: revenue ₹430 Cr (+18.8% YoY); EBITDA ₹16.99 Cr (margin 3.94% vs 7.92%); consolidated net loss ₹36.38 Cr; exceptional item ₹29.44 CrTrough quarter; goodwill write-off
21 May 2025FY25 results: consolidated revenue ₹1,536.7 Cr; net loss ₹108.2 Cr (owners ₹83.6 Cr; EPS -19.13); no dividendWorst loss in a decade
23 Jun 2025Trading window closed from 1 July 2025Routine
25 Jun 2025Public notice on transfer of shares to IEPFRoutine
29 Jul 2025Board approved divestment of the entire APAG stake (USD 19.38 Mn infusion; dilution to about 14.3%; tranche 2 FY2029-30)Strategic pivot to pure chemicals
31 Jul 2025APAG ceased to be a subsidiary (effective date per FY26 Directors' Report)Deconsolidation
5 Aug 2025Q1FY26: consolidated total income ₹454.5 Cr; consolidated loss ₹13.78 Cr; standalone revenue ₹186.6 Cr; standalone loss ₹7.67 Cr; APAG impairment ₹10.64 Cr; Electronic Automotive segment loss ₹9.68 CrPre-deconsolidation quarter
5 Aug–3 Sep 2025Postal ballot e-voting on APAG divestment—
3 Sep 2025—
4 Sep 2025Shareholders approved APAG divestment (99.98% in favour; 232 of 18,580 holders voted)Approval secured
15 Sep 2025Shareholders' agreement signed among APAG, Anevolve, Asia Investments UK, KCIL and CoSyst Holding AGDeal executed
10 Nov 2025Q2/H1FY26 results: consolidated net profit ₹93.44 Cr (gain on APAG)One-off profit
10 Nov 2025Sumanta Chaudhuri inducted into Audit CommitteeGovernance
28–30 Jan 2026Supreme Court dismissed CIT-IV Kolkata's appeal (Civil Appeal 13772/2015), following an earlier coordinate-bench ruling (Jindal Steel case, 6 Dec 2023); disclosed 30 JanFavourable tax precedent; company says no material impact
2 Feb 2026Clarification to exchanges on the Supreme Court disclosureDisclosure hygiene
12 Feb 2026Q3FY26: standalone revenue ₹230.6 Cr (+42% YoY); standalone PAT ₹3.93 Cr vs loss ₹19.7 Cr; consolidated revenue ₹265.8 Cr; consolidated PAT ₹3.55 CrOperational turnaround visible
1 Apr 2026EGM: authorised capital raised to ₹100 Cr (10 crore equity of ₹5 + 5 lakh preference of ₹1,000); NCRPS issue approvedCapital-structure change
13 Apr 2026Board approved Letter of Offer (PAS-4) for NCRPS—
18 Apr 20264,95,000 7% NCRPS (₹49.5 Cr) allotted to R.V. Investment and Dealers LtdPromoter funding of capex/working capital
23 Apr 2026Insider-trading disclosure on NCRPS allotmentCompliance
7 May 2026NSE sought clarification on significant price movementStock momentum
8 May 2026RTA changed to MUFG Intime India (merger with C B Management Services)Administrative
25 May 2026FY26 audited results: consolidated revenue ₹981.4 Cr (+30% on continuing basis); net profit ₹113.2 Cr (owners ₹120.8 Cr); no dividend; Suhana Murshed re-appointment recommended; auditors re-appointedReturn to profit
29 May 2026Annual Secretarial Compliance Report for FY26 notes filing delays and minor observationsGovernance watch-point
23 Jun 2026Trading window closed from 1 July 2026Routine
6–7 Aug 202666th AGM notice and FY26 annual report dispatched; FY26 standalone PAT ₹34.4 Cr—
11 Aug 2026Q1FY27: consolidated revenue ₹460.4 Cr (+129% YoY); EBITDA ₹51.8 Cr; PAT ₹26.4 Cr; standalone revenue ₹430.0 Cr; NCRPS fair-value gain ₹6.3 CrStep-change quarter
2 Sep 202666th AGM: all four resolutions passed (FY26 accounts; Khaitan re-appointment; Murshed re-appointment; cost-auditor fees FY27); Vision-2030 update (Triacetin/Penta derivatives "shortly"); geopolitics and tariffs flagged as threatsStrategy reaffirmed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 13,690 Mn in FY2022 to INR 9,810 Mn in FY2026.
Kanoria Chemicals & Industries Ltd. — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations13,69015,78014,75015,3709,810

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.